重点通报！司南导航慷慨派发年度股息 每10股派1.3元 彰显企业稳健发展与股东回报决心

司南导航慷慨派发年度股息 每10股派1.3元 彰显企业稳健发展与股东回报决心

上海 – 2024年6月14日 – 领先的导航及惯性测量系统解决方案供应商司南导航（股票代码：688592.SH）今日宣布，公司董事会审议通过了2023年度利润分配方案，拟向股东每10股派发现金红利1.3元（含税），共计分配现金红利人民币约2.1亿元。本次利润分配方案将于公司股东大会上提交审议，以获得股东批准。

股权登记日为6月20日

根据公司公告，本次利润分配的股权登记日为2024年6月20日。这意味着，凡在2024年6月20日（含当日）之前持有司南导航股票的股东，均有权获得本次利润分配。

慷慨回馈股东彰显企业实力

司南导航此次派发现金红利，体现了公司对股东的尊重与回报，以及公司稳健发展和持续盈利的能力。公司近年来业绩稳步增长，2023年实现营业收入人民币35.2亿元，同比增长18.5%；归属于上市公司股东的净利润人民币5.1亿元，同比增长20.8%。公司良好的财务状况为股东提供了丰厚的回报。

未来发展前景广阔

展望未来，司南导航将继续坚持“科技创新、卓越运营、价值创造”的发展战略，不断提升核心技术研发能力，持续优化产品结构，拓展市场应用领域，努力为股东创造更大价值。

关于司南导航

司南导航（股票代码：688592.SH）是中国领先的导航及惯性测量系统解决方案供应商，公司致力于为全球用户提供高精度、高可靠、高性价比的导航及惯性测量产品和系统解决方案。公司产品广泛应用于航空航天、兵器、船舶、测绘、石油勘探、无人机等领域。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.